Shiva Kumar, MBBS, is the Chief of Gastroenterology & Hepatology in the Digestive Disease Institute at Cleveland Clinic Abu Dhabi.
Prior to joining Cleveland Clinic Abu Dhabi, Dr. Kumar served as Medical Director of Liver Transplantation and Primary Liver Physician at two liver transplant centers in the US for more than eight years. He was also Director of Hepatology sub-specialty fellowship training at Ochsner Clinic in New Orleans, Louisiana, US, and Clinical Adjunct Associate Professor of Medicine at the University of Wisconsin School of Medicine & Public Health, US.
Dr. Kumar graduated from the University of Kerala Medical School in India and completed his residency and chief residency in Internal Medicine at Our Lady of Mercy University Medical Center in New York, US. He then pursued sub-specialty fellowship training in Gastroenterology & Hepatology at the Mayo Clinic in Rochester, Minnesota, US, and additional clinical and research training in Hepatology at the Liver Unit of the University of Texas Southwestern Medical Center in Dallas, Texas, US. He also completed his MSc in Healthcare Management from the University of Texas at Dallas, Jindal School of Management in Richardson, Texas, US.
Dr. Kumar is certified by the American Board of Internal Medicine (ABIM) in Internal Medicine, Gastroenterology & Transplant Hepatology and his primary areas of clinical and research interests include general-transplant hepatology and liver and hepatobiliary endoscopy.
He is a fellow of the American College of Gastroenterology (ACG), American College of Physicians (ACP), and American Society of Gastrointestinal Endoscopy (ASGE), and has served on many committees of national scientific societies including practice parameters and patient care committees of ACG and public and member outreach committee of the American Society of Gastrointestinal Endoscopy (ASGE).
Dr. Kumar has numerous publications and has delivered presentations at national and international scientific meetings, with a primary focus on liver disease and transplantation. He has also served as a primary site investigator in numerous clinical trials including those of newer therapeutic agents in hepatitis C.